Demographic And Clinical Characteristics Of Patients Prescribed Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor Therapy And Patients Whose Current Lipid-Lowering Therapy Was Modified

References

• Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association [published correction appears in Circulation. 2018;137(12):e493] Circulation. 2018;137(12):e67–e492. doi:10.1161/CIR.000000000000055829386200
   PubMed Web of Science ®Google Scholar
• The US Burden of Disease Collaborators. The State of US Health, 1990–2016: burden of diseases, injuries, and risk factors among US States. JAMA. 2018;319(14):1444–1472. doi:10.1001/jama.2018.015829634829
   PubMed Web of Science ®Google Scholar
• American Heart Association & American Stroke Association. Cardiovascular Disease: A Costly Burden for America — Projections through 2035. American Heart Association website Available from: https://healthmetrics.heart.org/wp-content/uploads/2017/10/Cardiovascular-Disease-A-Costly-Burden.pdf Accessed February 14, 2019.
   Google Scholar
• Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–2472. doi:10.1093/eurheartj/ehx14428444290
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Brown MS. A century of cholesterol and coronaries: from plaques to genes to statins. Cell. 2015;161(1):161–172. doi:10.1016/j.cell.2015.01.03625815993
   PubMed Web of Science ®Google Scholar
• Boekholdt SM, Hovingh GK, Mora S, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol. 2014;64(5):485–494. doi:10.1016/j.jacc.2014.02.61525082583
   PubMed Web of Science ®Google Scholar
• Wong ND, Chuang J, Zhao Y, Rosenblit PD. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009–2010. J Clin Lipidol. 2015;9(4):525–532. doi:10.1016/j.jacl.2015.05.00326228670
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–1722. doi:10.1056/NEJMoa161566428304224
   PubMed Web of Science ®Google Scholar
• Szarek M, White HD, Schwartz GG, et al. Alirocumab reduces total nonfatal cardiovascular and fatal events: the ODYSSEY OUTCOMES trial. J Am Coll Cardiol. 2019;73(4):387–396. doi:10.1016/j.jacc.2018.10.03930428396
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;73(24):e285–e359. doi:10.1016/j.jacc.2018.11.00330423393
   PubMed Web of Science ®Google Scholar
• Zafrir B, Jubran A. Lipid-lowering therapy with PCSK9-inhibitors in the real-world setting: two-year experience of a regional lipid clinic. Cardiovasc Ther. 2018;36(5):e12439 doi:10.1111/1755-5922.1243929863817
   PubMed Web of Science ®Google Scholar
• Baum SJ, Toth PP, Underberg JA, Jellinger P, Ross J, Wilemon K. PCSK9 inhibitor access barriers-issues and recommendations: improving the access process for patients, clinicians and payers. Clin Cardiol. 2017;40(4):243–254. doi:10.1002/clc.2271328328015
   PubMed Web of Science ®Google Scholar
• Hess GP, Natarajan P, Faridi KF, Fievitz A, Valsdottir L, Yeh RW. Proprotein convertase subtilisin/kexin type 9 inhibitor therapy: payer approvals and rejections, and patient characteristics for successful prescribing. Circulation. 2017;136(23):2210–2219. doi:10.1161/CIRCULATIONAHA.117.02843029084735
   PubMed Web of Science ®Google Scholar
• Rane PB, Patel J, Harrison DJ, et al. Patient characteristics and real-world treatment patterns among early users of PCSK9 inhibitors. Am J Cardiovasc Drugs. 2018;18(2):103–108. doi:10.1007/s40256-017-0246-z28849360
   PubMed Web of Science ®Google Scholar
• Lewis SJ, Olufade T, Anzalone DA, Malangone-Monaco E, Evans KA, Johnston S. LDL cholesterol levels after switch from atorvastatin to rosuvastatin. Curr Med Res Opin. 2018;34(10):1717–1723. doi:10.1080/03007995.2017.142114729271267
   PubMed Web of Science ®Google Scholar
• Schuster H, Barter PJ, Stender S, et al. Effects of switching statins on achievement of lipid goals: measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY I) study. Am Heart J. 2004;147(4):705–713. doi:10.1016/j.ahj.2003.10.00415077101
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681. doi:10.1016/S0140-6736(10)61350-521067804
   PubMed Web of Science ®Google Scholar
• Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316(12):1289–1297. doi:10.1001/jama.2016.1398527673306
   PubMed Web of Science ®Google Scholar
• Rubenfire M. Latest in Cardiology. American College of Cardiology website Available from: https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2018/11/09/14/28/2018-guideline-on-management-of-blood-cholesterol Accessed January 7, 2019.
   Google Scholar
• Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1500–1509. doi:10.1056/NEJMoa150085825773607
   PubMed Web of Science ®Google Scholar
• Cannon CP, Cariou B, Blom D, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015;36(19):1186–1194. doi:10.1093/eurheartj/ehv02825687353
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association [published correction appears in Circulation. 2017; 135(10):e646and Circulation. 2017;136(10):e196] Circulation. 2017;135(10):e146–e603. doi:10.1161/CIR.000000000000048528122885
   PubMed Web of Science ®Google Scholar
• Ortendahl JD, Diamant AL, Toth PP, Cherepanov D, Harmon AL, Broder MS. Protecting the gains: what changes are needed to prevent a reversal of the downward cardiovascular disease mortality trend? Clin Cardiol. 2019;42(1):47–55. doi:10.1002/clc.2309730318600
   PubMed Web of Science ®Google Scholar
• Menzin J, Aggarwal J, Boatman B, et al. Ezetimibe use and LDL-C goal achievement: a retrospective database analysis of patients with clinical atherosclerotic cardiovascular disease or probable heterozygous familial hypercholesterolemia. J Manag Care Spec Pharm. 2017;23(12):1270–1276. doi:10.18553/jmcp.2017.1641429172973
   PubMed Web of Science ®Google Scholar
• Chen CC, Rane PB, Hines DM, Patel J, Harrison DJ, Wade RL. Low-density lipoprotein cholesterol outcomes post-non-PCSK9i lipid-lowering therapies in atherosclerotic cardiovascular disease and probable heterozygous familial hypercholesterolemia patients. Ther Clin Risk Manag. 2018;14:2425–2435. doi:10.2147/TCRM.S18078330587999
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology task force on expert consensus decision pathways. J Am Coll Cardiol. 2017;70(14):1785–1822. doi:10.1016/j.jacc.2017.07.74528886926
   PubMed Web of Science ®Google Scholar
• Li S, Peng Y, Wang X, et al. Cardiovascular events and death after myocardial infarction or ischemic stroke in an older Medicare population. Clin Cardiol. 2019;42(3):391–399. doi:10.1002/clc.2316030697776
   PubMed Web of Science ®Google Scholar